title: Appearance of malignant melanoma after a non-cutaneous cancer diagnosis.
abstract: BACKGROUND
  The aim of this study is to find the associations between malignant melanoma (MM) and other non-cutaneous malignancies and to see whether there are possible correlations between them.
  
  
  METHODS
  We analysed a sample of 1720 patients collected by our melanoma database, to identify patients with both MM and non-cutaneous primary cancer (NCC). The incidence rate (IR) included in our database was calculated as the ratio between the observed patients with NCC and those with MM.
  
  
  RESULTS
  A total of 74 patients, with both NCC and MM, were included in our analysis, corresponding to 4.30% of patients with MM present in our melanoma database. After breast cancer (24.3%; IR = 1:4), the most common malignancies were lymphomas (14.8%; IR = 1:4), renal cell carcinoma (13.5%; IR = 1:7), thyroid cancer (9.4%; IR = 1:11), and prostatic carcinoma (8.1%; IR = 1:12), followed by other cancers. Among patients with lymphomas, most patients (72.7%) had a non-Hodgkin lymphoma. Our study shows a high coexistence of multiple malignancies in patients with MM.
  
  
  CONCLUSIONS
  Although we cannot definitively confirm a true association between non-skin cancers and MM, we believe that there are sufficient links for further investigation in order to identify new aetiological factors and therapeutic targets for these cancers.
authors: University Magna Graecia, V.le Europa, 88100 Catanzaro, Italy.
authors: Ugo
authors: U
authors: Bottoni
authors: Rita
authors: R
authors: Clerico
authors: Giovanni
authors: G
authors: Paolino
authors: Marina
authors: M
authors: Ambrifi
authors: Cecilia
authors: C
authors: Luci
authors: Paola
authors: P
authors: Corsetti
authors: Stefano
authors: S
authors: Calvieri
keywords: melanoma; multiple primary malignancies; non-cutaneous malignancies; renal cell carcinoma; thyroid cancer
references: Eur Urol. 2009 Jun;55(6):1490-1
references: 19282104
references: Pigment Cell Melanoma Res. 2013 Mar;26(2):259-62
references: 23167872
references: Clin Cancer Res. 2008 Nov 15;14(22):7358-66
references: 19010851
references: N Engl J Med. 1995 Oct 12;333(15):975-7
references: 7666917
references: Cancer. 2010 Dec 15;116(24):5716-24
references: 21218461
references: Ann Oncol. 2008 Jul;19(7):1340-1346
references: 18325912
references: Eur Urol. 2011 Nov;60(5):987-93
references: 21621909
references: Br J Dermatol. 2001 Dec;145(6):981-5
references: 11899153
references: Arch Dermatol. 2010 Mar;146(3):265-72
references: 20231496
references: Int J Clin Exp Med. 2012;5(4):310-5
references: 22993650
references: Curr Mol Med. 2009 Dec;9(9):1058-79
references: 19747114
references: Cancer. 1999 Nov 15;86(10):2014-20
references: 10570426
references: Fam Cancer. 2011 Sep;10(3):545-8
references: 21614589
references: Med Sci (Paris). 2012 Mar;28(3):258-61
references: 22480646
references: Clin Exp Dermatol. 2013 Jan;38(1):47-9
references: 22681124
references: Ann Intern Med. 2008 May 20;148(10):728-36
references: 18490686
references: Br J Cancer. 1996 Jan;73(2):255-9
references: 8546916
references: Cancer Res. 2003 Dec 15;63(24):8735-41
references: 14695188
references: J Clin Oncol. 2009 Dec 20;27(36):6199-206
references: 19917835